On October 8, INSILICO fell 5.7% in regular trading, trading at HK$49.98 with turnover of HK$298 million.

The decline was driven by a collective pullback in the AI drug sector after recent consecutive gains, prompting investors to lock in profits. A day earlier, the stock had already dropped 10.62%, while sector peer XTALPI fell 12.1%, reflecting broad-based selling across AI-driven innovative drug names.

Market analysis indicates that while AI-driven drug discovery remains a long-term industry trend, most companies are still in the pipeline validation stage, with long commercialization cycles and limited near-term cash flow. After rapid valuation expansion, profit-taking pressure has intensified. INSILICO operates an AI-powered drug discovery and pipeline development business through its proprietary Pharma.AI platform, with additional exposure to software solutions and non-pharmaceutical R&D.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)